NCT00790049: ARRY-371797 in healthy adults: early safety study

Medicine Signal Editorial Desk
Updated 2026-10-10

Registry status when checked 2026-10-10Completed

Study: Early safety and pharmacokinetic testing of oral ARRY-371797, a p38 inhibitor, in healthy adults. 1 2

Design and measurements: This phase I study used randomized, double-blind, placebo-controlled, ascending-dose testing, including single-day and eight-day dosing. The structured record lists 40 actual participants, while the narrative describes a plan for 48. Eligibility describes healthy adults aged 18–60; an inconsistent structured healthy-volunteer flag should not override that description without qualification. 1 2

What is established: The record is marked completed and was updated in April 2022. Numerical drug-exposure and adverse-event findings were not verified. This is a healthy-volunteer pharmacology study; efficacy findings from later studies in patients with cardiomyopathy cannot be assigned to this identifier. 1 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT00790049. Original study registration: sponsor, design, population, endpoints and dated history.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT00790049. Original study registration: sponsor, design, population, endpoints and dated history.

2. ICH GCP — ICH GCP — readable reproduction of the sponsor-submitted ClinicalTrials.gov record. Supports the registration details quoted here; not an independent clinical-results publication.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.